Thomas Barringer, MD
Family Medicine · Charlotte, NCNPI 1811918485
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $117,229 of the $137,591 with a category attached, or 85.2%. 20 manufacturers reported payments, led by Amarin Pharma, Inc. at 38.4% of the total. Reporting peaked in 2019 at $67,430 and has fallen 94.4% since, to $3,742 in 2025. Among family medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $486.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$53K
- Esperion Therapeutics, Inc.$38K
- Sanofi-aventis U.S. LLC$16K
- Amgen$15K
- Medicure Pharma Inc.$5K
- Novo Nordisk$5K
- plus $6K from 14 others
Across 58 payments — averaging $2981.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$71K
- Ionis Pharmaceuticals, Inc.$59K
- Sanofi US Services Inc.$43K
What the payments were for
- Consulting fees$9,4337%
- Speaking & faculty fees$117,22985%
- Travel & lodging$2,6082%
- Food & beverage$8,3146%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 55 | $52,779 |
| Esperion Therapeutics, Inc. | 65 | $37,917 |
| Sanofi-aventis U.S. LLC | 12 | $16,434 |
| Amgen | 48 | $14,693 |
| Medicure Pharma Inc. | 2 | $5,000 |
| Novo Nordisk | 20 | $4,740 |
| Novartis | 31 | $2,508 |
| Regeneron Healthcare Solutions, Inc. | 1 | $1,222 |
| AstraZeneca | 8 | $837 |
| Boehringer Ingelheim | 10 | $422 |
| Heartflow, Inc. | 7 | $251 |
| Kowa Pharmaceuticals America, Inc. | 10 | $197 |
| Boston Scientific | 2 | $139 |
| Xeris Pharmaceuticals, Inc. | 2 | $129 |
| Akcea Therapeutics, Inc. | 1 | $103 |
| Chiesi USA, Inc. | 3 | $68 |
| Bayer | 1 | $54 |
| Lilly USA, LLC | 2 | $44 |
| Ionis Pharmaceuticals, Inc. | 2 | $38 |
| Cook Medical LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$51,639
- NEXLIZET$36,980
- NEXLETOL$36,980
- PRALUENT$14,500
- Repatha$13,796
- ZYPITAMAG (pitavastatin)$5,000
- DISEASE STATE$3,140
- LEQVIO$1,868
- Ozempic$1,410
- FARXIGA$592
- JARDIANCE$126
- Watchman$121
- FFRct$119
- GVOKE HYPOPEN$112
- TEGSEDI$103
How this compares
$137,591 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 1,172 | $931,998 |
| Praluent PenAlirocumab | 362 | $250,585 |
| TrulicityDulaglutide | 47 | $60,863 |
| EliquisApixaban | 61 | $56,209 |
| JardianceEmpagliflozin | 32 | $42,267 |
| VascepaIcosapent Ethyl | 59 | $34,966 |
| OzempicSemaglutide | 30 | $34,715 |
| LivaloPitavastatin Calcium | 47 | $30,737 |
| Ezetimibe | 1,398 | $29,808 |
| NexlizetBempedoic Acid/Ezetimibe | 27 | $22,395 |
| Repatha SyringeEvolocumab | 39 | $20,808 |
| NexletolBempedoic Acid | 11 | $12,065 |
| Pitavastatin Calcium | 40 | $9,343 |
| Rosuvastatin Calcium | 706 | $7,957 |
| Icosapent Ethyl | 24 | $7,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $44 | $60,86347 claims |
| Boehringer IngelheimJardiance | $422 | $42,26732 claims |
| Novo NordiskOzempic | $4,740 | $34,71530 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $37,917 | $34,46038 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $197 | $30,73747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Charlotte
- Kevin SodenCharlotte$558K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- William LarsenCharlotte$74K
- William LongCharlotte$66K
- Steven BauerCharlotte$22K
- Tagbo EkwonuCharlotte$20K
- Rhett BrownCharlotte$18K
- George RaadCharlotte$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.